Zonisamide for Weight Reduction in Obese Adults
唑尼沙胺用于肥胖成人减肥
基本信息
- 批准号:6868043
- 负责人:
- 金额:$ 31.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Obesity prevalence in the US has risen to epidemic proportions. Pharmacotherapy is indicated for weight reduction in patients with body mass index (BMI) >=30 kg/m 2 as well as those with BMI >=27 kg/m 2 in the presence of co-morbid risk factors. However, currently there are very few pharmacologic treatment options for weight reduction, and the available treatments fail to provide adequate benefit for many obese patients because of lack of efficacy, side effects, or contraindications. Hence, there is considerable need for developing new treatments for the management of obesity.
Zonisamide, a drug that is currently marketed as an antiepileptic, has been shown to promote significant weight loss in obese patients in a 16-week preliminary investigation conducted by our group. However, the pharmaceutical company that has exclusive marketing rights for zonisamide in the US will not conduct further studies of longer duration with a larger sample of patients to seek a new indication, as the market exclusivity on this drug is due to expire in less than two years.
Because Zonisamide can be a potential weapon in our fight against obesity, we wish to pursue this idea further via a randomised clinical trial examining the efficacy of the drug over a year. Since our preliminary trial design did not allow us to assess whether a smaller dose of zonisamide might also be effective, we will examine dose-response in this study in addition to assessment of long-term efficacy and safety. We will also systematically assess whether weight loss achieved with zonisamide treatment can reduce metabolic and cardiovascular risk factors.
描述(由申请人提供):美国的肥胖患病率已上升到流行病的比例。药物治疗适用于体重指数(BMI)≥ 30 kg/m2以及BMI ≥ 27 kg/m2且存在共病风险因素的患者的体重减轻。然而,目前用于减轻体重的药物治疗选择很少,并且由于缺乏疗效、副作用或禁忌症,可用的治疗未能为许多肥胖患者提供足够的益处。因此,非常需要开发新的治疗方法来管理肥胖症。
唑尼沙胺,一种目前作为抗癫痫药上市的药物,在我们小组进行的一项为期16周的初步研究中,已被证明能促进肥胖患者的体重显著减轻。然而,在美国拥有唑尼沙胺独家营销权的制药公司将不会在更大的患者样本中进行更长时间的进一步研究以寻求新的适应症,因为该药物的市场独占权将在不到两年的时间内到期。
由于唑尼沙胺可以成为我们对抗肥胖的潜在武器,我们希望通过一项为期一年的随机临床试验来进一步研究这种药物的疗效。由于我们的初步试验设计不允许我们评估较小剂量的唑尼沙胺是否也可能有效,因此我们将在本研究中检查剂量反应以及长期疗效和安全性评估。我们还将系统地评估唑尼沙胺治疗实现的体重减轻是否可以减少代谢和心血管风险因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KISHORE M GADDE其他文献
KISHORE M GADDE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KISHORE M GADDE', 18)}}的其他基金
Pharmacotherapy in conjunction with lifestyle counseling for management of weight regain after bariatric surgery (PROJECT-BARI)
药物治疗与生活方式咨询相结合,用于控制减肥手术后的体重恢复(PROJECT-BARI)
- 批准号:
10701046 - 财政年份:2022
- 资助金额:
$ 31.57万 - 项目类别:
Pharmacotherapy in conjunction with lifestyle counseling for management of weight regain after bariatric surgery (PROJECT-BARI)
药物治疗与生活方式咨询相结合,用于控制减肥手术后的体重恢复(PROJECT-BARI)
- 批准号:
10678557 - 财政年份:2022
- 资助金额:
$ 31.57万 - 项目类别:
Pharmacotherapy in conjunction with lifestyle counseling for management of weight regain after bariatric surgery (PROJECT-BARI)
药物治疗与生活方式咨询相结合,用于控制减肥手术后的体重恢复(PROJECT-BARI)
- 批准号:
10280812 - 财政年份:2021
- 资助金额:
$ 31.57万 - 项目类别:
相似海外基金
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 31.57万 - 项目类别:
CAPRISA CASCADE Clinical Trials Network Clinical Research Site
CAPRISA CASCADE 临床试验网络临床研究网站
- 批准号:
10754981 - 财政年份:2023
- 资助金额:
$ 31.57万 - 项目类别:
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN)
提供生物医学和行为研究资源以及临床研究协调服务以支持 NIDA 临床试验网络 (CTN)
- 批准号:
10617997 - 财政年份:2022
- 资助金额:
$ 31.57万 - 项目类别:
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN)
提供生物医学和行为研究资源以及临床研究协调服务以支持 NIDA 临床试验网络 (CTN)
- 批准号:
10538151 - 财政年份:2021
- 资助金额:
$ 31.57万 - 项目类别:
Admin. Supp. for NCI P30 Cancer Center Grants to Facilitate the Development of Standardized Electronic Treatment Plan Builds for NCI-Supported Clinical Trials Applicable Across Clinical Research Sites
行政。
- 批准号:
10442122 - 财政年份:2021
- 资助金额:
$ 31.57万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10624966 - 财政年份:2021
- 资助金额:
$ 31.57万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10515803 - 财政年份:2021
- 资助金额:
$ 31.57万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10258627 - 财政年份:2021
- 资助金额:
$ 31.57万 - 项目类别:
New Mexico Clinical Trials Node: Clinical research and practice to address substance use in diverse, rural and underserved populations
新墨西哥州临床试验节点:解决多样化、农村和服务不足人群的药物使用问题的临床研究和实践
- 批准号:
10581505 - 财政年份:2019
- 资助金额:
$ 31.57万 - 项目类别:
New Mexico Clinical Trials Node: Clinical research and practice to address substance use in diverse, rural and underserved populations
新墨西哥州临床试验节点:解决多样化、农村和服务不足人群的药物使用问题的临床研究和实践
- 批准号:
10379715 - 财政年份:2019
- 资助金额:
$ 31.57万 - 项目类别:














{{item.name}}会员




